42 results about "Stem cell population" patented technology

Therefore, this disclosure provides a genetically engineered mesenchymal stem cell (MSC) population, including an expression vector containing the Akt or HGF gene and the PD-L1 gene. It also provides a method for synergistically improving the survival status and immunomodulatory capacity of mesenchymal stem cells or enhancing their proliferation, including transfecting mesenchymal stem cells with the Akt or HGF gene and the PD-L1 gene; and a method for preventing, improving, and / or treating ischemic conditions, enhancing neurogenesis, or reducing neuronal death, including administering an effective amount of the genetically engineered mesenchymal stem cell population of this disclosure to individuals in need.

Genetically modified zebrafish, in which mutation combinations frequently identified in human AML are stably expressed in the stem cell population of the fish, are provided. The combination of mutations result in morphologic, cytochemical and molecular changes of its blood cells that are remarkably similar to those in human AML. The zebrafish model provides a foundation for the study of AML initiation and progression and a high throughput in vivo drug screening platform to identify personalized therapies for AML based on specific mutation combinations. The method of drug screening includes contacting embryos or adult fish containing mutations as disclosed herein, with a test agent, at test concentrations and test intervals to determine the therapeutic effect if any, of the test agent.

The present disclosure relates to a method for two-dimensionally culturing an intestinal stem cell population in a chemically defined medium and a use thereof, and also relates to a method for differentiating the intestinal stem cell population into 2.5-dimensional intestinal epithelial cells and a use thereof.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

Novel populations of canine derived stem cells useful for treatment across allogeneic barriers. The stem cells can be of mesenchymal lineage optimized to possess enhanced proliferative activity in vitro and in vivo without significant loss of therapeutic functionality. Said therapeutic activities include angiogenesis, stimulation of growth factor production, antifibrotic effects, neurogenesis, immune modulation, and antiapoptotic effects.

The invention belongs to a cell culture technology in the field of biomedicine, and particularly relates to a liver organoid for traditional Chinese medicine screening and toxicity assessment and a construction method and application thereof. The construction method comprises the following steps: carrying out plane multiplication culture on pluripotent stem cells, then digesting and subculturing, and repeating to obtain a cell culture medium; a pluripotent stem cell group which is uniform in cell morphology and free of spontaneous differentiation is obtained; performing two-dimensional plane directional induction on the pluripotent stem cell population to enable cells to synchronously and uniformly receive differentiation signals to obtain hepatogenic mother cells; culturing the obtained hepatic mastocytes by using a culture medium E under a three-dimensional suspension condition to promote the specificity and balling of the hepatic lineage; the culture medium E is an Advanced DMEM / F12 which comprises 1 to 5 [mu] M of RA, 2 to 10 [mu] M of Y-27632, 0.5 to 1 [mu] M of beta-nicotinamide mononucleotide, 5 to 10 [mu] M of senkyunolide A, B27 and N2; and then replacing the culture medium to further mature and functionalize the hepatocytes to obtain the liver organoid, and the obtained liver organoid has high stability, high uniformity, good survival rate and mature hepatocyte functions.

To clarify the heterogeneous composition of mesenchymal stromal / stem cells (MSCs) and identify functional subpopulations of MSCs.SOLUTION: Provided is a method for identifying functional cell subpopulations in a cell population of MSCs, comprising: performing omics analysis of the cell population of MSCs at the single cell level; and clustering the cell population of MSCs based on the results of the analysis to classify it into cell subpopulations.SELECTED DRAWING: None

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

The present invention provides methods and systems for enhanced production and / or secretion of extracellular vesicles from at least one three-dimensional porous scaffold having a population of stem cells cultured thereon, utilizing various shear stress conditions on a variety of stem cells.

Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and / or allogenic HSCs, using mechanical stretching or Trpv4 agonists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and / or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.

The present invention relates to a method of inducing or improving wound healing properties of a mesenchymal stem cell population, the method comprising cultivating the mesenchymal stem cell population in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.

The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.

This method for estimating the therapeutic effect of stem cell transplantation comprises: a step (S11) for acquiring a plurality of cell images in which a stem cell group in culture is imaged at a plurality of predetermined time points within a cell culturing period for stem cell transplantation for regenerative medicine purposes; a step (S12) for identifying stem cell regions respectively in the plurality of cell images; a step (S13) for acquiring, on the basis of the identified stem cell regions, a plurality of types of index values associated with the stem cell group with respect to each of the plurality of cell images; and a step (S14) for estimating, before the transplantation of the stem cell group obtained by the cell culturing, the therapeutic effect of the transplantation of the stem cell group on the basis of the acquired plurality of types of index values. The plurality of types of index values acquired in step (S13) include a plurality of types of index values associated with the morphologies of the stem cells.

The present invention relates to methods for expanding a stem cell population, as well as other cell populations. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell and / or other cell population, particularly a hematopoietic stem cell population.

The disclosure is drawn to an isolated somatic stem cell population including somatic stem cells that are PD-L1+ and methods of using the isolated somatic stem cell population to modulate an immune response.

The invention relates to the technical field of vaccines, in particular to a VP2 protein gene modification-based feline panleucopenia virus vaccine as well as a preparation method and application thereof, the amino acid sequence of VP2 protein of feline panleucopenia virus is shown as SEQ ID NO.2, and the nucleotide sequence is shown as SEQ ID NO.1. The invention further discloses a preparation method of the VP2 protein gene modification-based feline panleucopenia virus vaccine. Cell therapy and gene therapy are combined, the VP2 protein modified mesenchymal stem cells serve as active ingredients of the vaccine, the vaccine has the advantage of being convenient to obtain, the number of local stem cells can be supplemented, VP2 protein and human-derived growth factors (such as EGF and bFGF) can be efficiently secreted, the local microenvironment and immune regulation are improved, and meanwhile, the VP2 protein modified mesenchymal stem cells can be used for preparing the vaccine. The polypeptide can stimulate the body to generate a neutralizing antibody aiming at the feline panleukopenia virus, is safe, reliable and effective, has a good application prospect, and provides a brand new choice for preventing the feline panleukopenia virus.

The present invention relates to a method for expanding a population of stem cells obtained from a tissue selected from the group consisting of peripheral blood, umbilical cord blood and bone marrow, a method for expanding a population of stem cells as well as other populations of cells. More particularly, the present invention relates, inter alia, to methods and compositions for expanding stem cells and / or other cell populations, in particular hematopoietic stem cell populations.

The present invention provides a method for identifying functional cell subpopulations in an MSCs cell population, the method comprising performing omics analysis of an MSCs cell population at the single cell level and clustering the MSCs cell population based on the results of the analysis to classify the cell population into cell subpopulations.

This invention relates to a method for evaluating the wound-healing efficacy of mesenchymal stem cell (MSC) populations. Furthermore, this invention relates to a method for selecting MSCs for generating stem cell populations under cGMP conditions, and a method for selecting MSC populations for generating stem cell populations for subsequent drug administration. Additionally, this invention relates to a method for selecting MSC populations for generating a master cell bank, and a method for identifying tissues suitable as starting materials for generating MSC populations for drug use. The method includes measuring the levels of at least two proteins selected from angiopoietin-1 (Ang-1), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) secreted by MSCs into the culture medium.

The present invention relates to a method of inducing or improving wound healing properties of a population of mesenchymal stem cells, the method comprising culturing the population of mesenchymal stem cells in a culture medium comprising DMEM (Dulbecco Modified Eagle Medium), F12 (Hamm F12 Medium), M171 (Medium 171) and FBS (fetal calf serum). The present invention also relates to a population of mesenchymal stem cells wherein at least about 90% or more of the cells of the population of stem cells express each of the following markers: CD73, CD90 and CD105 and lack the expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of the mesenchymal stem cell population.

Provided are methods to increase the nephron yield and control over nephron locations in kidney organoids and kidney replacement tissues; the methods achieve spatiotemporal control over the mechanical microenvironment to engineer favorable environments for nephron formation within kidney organoids. This engineered control can be created using microdevices that impose mechanical stress at defined intervals synchronized with cyclical nephron development in vivo, agonists / antagonists of tension-generating biochemical pathways in whole organoids or cells, optogenetic control over tension in stem cell collectives, and / or cell-cell junction mediated transfer of mechanical information between cells, or similar approaches.

The invention provides colostrum derived stem cell populations, compositions and supplements having antimicrobial properties for enhancing mammalian health and for treating or preventing microbial contamination or infection. Also provided are methods of producing these populations, compositions and supplements from a female mammal in an inflammatory state. Also provided are colostrum derived stem cell populations and method of inducing differentiation into neural cells in neural progenitor medium including mammalian cell culture medium supplemented with casein depleted fraction of whey derived from colostrum. Also provided are neural progenitor medium, population of in vitro differentiated neural cells and pharmaceutical compositions containing same for use in treating neurological disease or disorder.

An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying the expression of the cell adhesion molecule in the population of isolated mammalian stem cells to decrease or knockout expression of the cell adhesion molecule and provide the population of hypoimmune mammalian cells. The population of isolated mammalian stem cells can be pluripotent stem cells, or embryonic stem cells, and can be human or non-human stem cells.

The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.

The present disclosure relates to a compound of formula (I)where R1 is as defined herein. The compound of formula I is an inhibitor of the dephosphorylation of phosphorylated elF2α. The phosphorylation of elF2α affects the quiescence and self renewal properties of stem cells such as muscle stem cells. The compound of formula (I) can thus be used to expand stem cells populations and treat degenerative diseases that have a quiescence regulation affected or mediated by the phosphorylation of elF2α.

Certain populations of small cells present in adult human tissue can undergo activation / development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation / development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.

To provide a culture medium for expanding and differentiating a stem cell population and for obtaining an organoid.SOLUTION: The culture medium for expanding and / or differentiating an adult stem cell population comprises i. any one of R-spondin and / or an R-spondin mimetic and ii. one or more inhibitors that directly or indirectly negatively regulate TGF-β signal transduction. The inhibitor binds to one or more serine / threonine protein kinases selected from ALK 5, ALK 4, TGF-β receptor kinase 1 and ALK 7, the activity of which is reduced by the culture medium. The culture medium further comprises one or more additional components selected from BMP inhibitors, Wnt agonists, receptor tyrosine kinase ligands, Bock inhibitors, nicotinamide and gastrin.SELECTED DRAWING: None

Culture media and methods for the expansion and differentiation of stem cell populations and for obtaining organoids. Expanded cell populations and organoids obtainable by the methods of the invention and their use in drug screening, toxicity testing, and regenerative medicine.